Amgen (AMGN)
(Delayed Data from NSDQ)
$269.98 USD
+0.60 (0.22%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $270.08 +0.10 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AMGN 269.98 +0.60(0.22%)
Will AMGN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AMGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMGN
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for
AMGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
Why Amgen (AMGN) Outpaced the Stock Market Today
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
Other News for AMGN
Amgen’s Blincyto data send Cullinan higher
AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY
Amgen announces imminent submission of MAA to EMA for teprotumumab
O'Keefe Stevens Advisory Q1 2024 Investor Letter
Diving Into Deciphera Pharmaceuticals